Press Kit

About CELLINK → www.cellink.com

CELLINK is the first bioink company in the world that focuses on the development and commercialization of bioprinting technologies that allow researchers to 3D print human organs and tissues for the development of pharmaceutical and cosmetic treatments. CELLINK’s innovative and patent pending bioink is a biomaterial innovation that enables human cells to grow and thrive such as they would in the natural human body environment. This is an ideal material for tissue engineering and life science applications.

Today, the company’s disruptive technology platform is being utilized to print tissues such as cartilage, skin, and even fully functional cancer tumors that can then be used to develop new cancer treatments. The company has, within 12 months, been able to commercialize products in approximately 40 countries and sold to more than hundreds of prestigious labs around the world, such as Harvard, MIT, Princeton, and FDA.

The company has managed to turn profitable within only 3 months of operations as the strong focus has been on global sales and succeeding to get products out the door. CELLINK’s largest market today is North America, followed by Europe, and Asia. The company was started on the 27 th of January 2016 in Gothenburg, Sweden by Erik Gatenholm and Hector Martinez. The focus was to change the world of medicine by disrupting the entire medical research industry. On the 3 rd of November (only 10 months after starting) CELLINK made an IPO on the NASDAQ stock exchange in Stockholm to raise funding.

CELLINK has offices in Gothenburg, Sweden, Cambridge, MA, Blacksburg, VA and Kyoto, Japan.